QUANTA-CLOUD-TECHNOLOGY
26.7.2022 05:53:13 CEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, today announced the world’s first validation of Samsung PM1743 PCIe Gen5 SSDs in their new all-flash NVMe™ servers powered by 4th Gen Intel® Xeon® Scalable processors. 4th Gen Intel Xeon Scalable processors will deliver substantial compute performance across traditional data center usages with unique purpose-built workload optimizations for today’s edge to cloud models. These technology updates in QCT’s growing line of QuantaGrid servers add additional performance for Samsung’s high-bandwidth flash storage due to the 4th Gen Intel Xeon Scalable processors support of leading industry standard technologies such as DDR5, Intel® Optane™ persistent memory, and PCIe Gen5. Furthermore, these unique solutions provide flexibility for modern data center needs ranging from low latency applications to data processing, and hyper-converged infrastructures (HCI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005386/en/
To accommodate the rapidly increasing performance requirements of data centers, PCIe Gen5 doubles IOPS per watt and throughput compared to the previous generation. Samsung’s PM1743 SSD for enterprise servers integrates the PCIe Gen5 interface with Samsung’s advanced sixth-generation V-NAND to deliver 30% enhanced power efficiency than the previous generation, resulting in lower server operating costs and increasing scalability for virtualized environments like HCI and software-defined storage.
With the evolution of data centers to the rapid growth of data and proliferation of applications that demand high performance, QCT’s upcoming QuantaGrid series offer flexibility for scaling out with Samsung’s new storage innovation. The QuantaGrid D54X-1U and D54Q-2U are designed for dual 4th Gen Intel Xeon Scalable processors with 32 DDR5 DIMM slots and support for Intel Optane persistent memory, which provides affordable memory capacity expansion and support for data persistence. The two servers mainly differ in storage capacity and number of expansion slots that will be further revealed with the release of 4th Gen Intel Xeon Scalable processors.
“QCT worked closely with Samsung to test and be among the first to validate Samsung’s PM1743 PCIe Gen5 SSDs on our Intel powered systems,” said Mike Yang, President of QCT. “Together with Samsung, and Intel, our technology leadership will continue to drive new applications as we accelerate the growth of the server market and deliver unparalleled performance advantages for IOPS-intensive applications.”
"Samsung has been working closely with QCT and Intel to show PCIe Gen5 PM1743 SSDs provide optimized performance for all-flash NVMe workloads in their QuantaGrid 1U and 2U systems," said Yongcheol Bae, Executive Vice President of the Memory Application Engineering Team at Samsung Electronics. “Collectively, with the introduction of our PCIe Gen5 SSD, Intel’s 4th Gen Xeon Scalable processors, and QCT’s QuantaGrid server line we will further solidify our technological leadership in the enterprise server market.”
“Our goal is to deliver industry leadership to accelerate data center performance and user experiences with our upcoming 4th Gen Intel Xeon Scalable processors,” said Zane Ball, Intel Corporate Vice President and General Manager of Data Platforms Engineering and Architecture. “The collaboration with QCT and Samsung signifies Intel’s commitment to providing our customers with a multitude of ways to enhance their applications with high-speed NVMe SSDs that enable deployments from edge to cloud.”
Follow QCT on Facebook and Twitter to receive their latest news and announcements.
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About QCT
QCT is a global datacenter solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. www.QCT.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005386/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fourthline and Veridas Complete Merger to Create a European Leader in Bank-Grade Digital Identity3.11.2026 13:40:00 CET | Press release
One provider for identity, compliance and fraud prevention across 50+ countries, with a single integrated platform. Fourthline and Veridas combined will create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US; on track for 200 million verifications in 2026. With a projected combined revenue of more than €50m in 2026 and both businesses EBITDA-positive at closing, the company expects to reach €85m annual recurring revenue in 2029. Financials: The transaction includes funding of up to €65m provided by existing shareholder Finch Capital, new equity investment from Seaya Andromeda and debt financing from Ashgrove Capital. Fourthline and Veridas today announce the completion of their merger, first announced on 16 July 2026. The transaction closed on 3 November 2026 following the satisfaction of all closing conditions. This press release features multimedia. View the full rele
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 12:30:00 CET | Press release
Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share COMP360 expected to fit seamlessly into current treatment
Vedanta Limited Delivers Highest-ever Half-yearly Profit of $1.21 bn, up 151% YoY3.11.2026 12:26:00 CET | Press release
Indian multinational Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals and critical minerals, announced its consolidated results for the second quarter and half year ended 30 September 2026, delivering its best-ever financial performance driven by operational excellence and disciplined execution. Vedanta Limited achieved its highest-ever quarterly Profit of $649 mn, up 151% YoY, while half-yearly Profit reached a record $1.21 bn, up 151% YoY. Vedanta also declared its first interim dividend of INR 5 per share during the quarter, reinforcing its commitment to shareholder returns. The Company delivered record quarterly revenue of $2.70 bn, up 57% YoY, taking half-yearly revenue to a record $5.18 bn, up 54% YoY. Quarterly EBITDA surged 106% YoY to $1.04 bn, while half-yearly EBITDA reached a record $1.94 bn, up 103% YoY. EBITDA margins expanded to 60% in Q2 and 58% in H1, improving by 1,055 bps and 1,023 bps YoY, respectively. Vedanta further strengthened its balance sh
BeOne Medicines to Present at the Jefferies Global Healthcare Conference3.11.2026 12:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.b
Dubai Culture Unveils ISEA2026 Online Academic Programme3.11.2026 11:58:00 CET | Press release
Dubai Culture and Arts Authority has unveiled the academic programme for the 31st International Symposium on Electronic/Emerging Art (ISEA2026), taking place in Dubai from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data, and Identity’. The symposium will explore the intersections of art, science and technology and examine the future of electronic arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103057351/en/ Dubai Culture unveils ISEA2026 Online Academic Programme (Photo: AETOSWire) The symposium, organised by Dubai Culture in partnership with Zayed University, is set to be the largest edition in its history. It will feature opening remarks by Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture, and Her Excellency Hala Badri, Director General of Dubai Culture, alongside keynote presentations by Katherine Hayles, Distinguished Research Professor at the U
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom